- βGLP-1 receptor PET imaging can now detect residual beta cells in long-standing Type 1 diabetes β previously considered impossible
- βBCM imaging is being integrated into landmark trials like VX-880, shifting from indirect blood markers to direct cell-counting evidence
- βNIH-backed standardization efforts through the Beta Cell Biology Consortium are accelerating a path toward clinical validation
Why Measuring Beta Cells Matters
At the heart of both Type 1 and Type 2 diabetes is the loss or dysfunction of beta cells β the specialized cells in the pancreas that produce insulin. For decades, doctors had no way to measure how many beta cells a patient actually has while they're alive. The only way to count them was through autopsy tissue. This has been one of the biggest blind spots in diabetes research and care.
Without knowing a patient's beta cell mass (BCM), it's impossible to predict who will develop diabetes, how fast the disease is progressing, or whether a treatment is actually protecting or restoring those cells. New imaging technologies are finally beginning to change that.
The Gold Standard Problem
Currently, doctors estimate beta cell function using indirect blood tests β C-peptide levels, Mixed Meal Tolerance Tests (MMTs), and glucose clamps. These tests measure what beta cells do, not how many exist. A patient could have very few beta cells working overtime, or many cells barely functioning. The number looks the same on a blood test. That's a critical gap in our understanding.
PET Imaging: The Most Promising Approach
Positron emission tomography (PET) scanning is currently the leading technology for non-invasive beta cell imaging. The challenge is finding a radioactive tracer that binds specifically to beta cells and nothing else in the pancreas.
The most studied tracer is [11C]-dihydrotetrabenazine (DTBZ), which targets a protein called VMAT2 that is highly expressed in beta cells. Early studies at the University of Pittsburgh and through collaborations with the Juvenile Diabetes Research Foundation (JDRF) showed that VMAT2-PET could detect differences in beta cell mass between healthy individuals and people with Type 1 diabetes. However, VMAT2 is also expressed in nerves throughout the pancreas, which created significant background noise that made precise measurements difficult.
More recent work has focused on glucagon-like peptide-1 receptor (GLP-1R) PET imaging. The tracer [68Ga]-exendin-4 binds directly to GLP-1 receptors, which are far more specific to beta cells than VMAT2. Studies published in Diabetes Care and The Journal of Nuclear Medicine have demonstrated that GLP-1R-PET can distinguish between healthy subjects, people with Type 1 diabetes, and even identify residual beta cell mass in long-standing Type 1 diabetes β something previously thought impossible.
The IMPROVE-T1D and Related Trials
Several clinical programs are now using BCM imaging as an outcome measure. Vertex Pharmaceuticals' landmark VX-880 trial β testing stem cell-derived islet transplantation β uses C-peptide and insulin independence as endpoints, but emerging protocols are pushing for PET-based BCM confirmation to verify that transplanted cells are surviving and functioning in situ. This represents a major shift: moving from indirect blood markers to direct cell counting.
The PROTECT trial, which evaluated teplizumab (Tzield) in newly diagnosed Type 1 diabetes, highlighted the critical need for better BCM measurement tools. Researchers could measure that the drug slowed C-peptide decline, but couldn't directly confirm whether beta cells were being preserved or simply working harder. GLP-1R-PET could answer that question in future trials.
The NIH-funded Beta Cell Biology Consortium (BCBC) has been a major driver of BCM imaging research, coordinating efforts across multiple academic centers to standardize imaging protocols and validate tracers for eventual FDA approval.
MRI-Based Approaches
PET requires radiation exposure and expensive cyclotron-produced tracers. Researchers are also exploring magnetic resonance imaging (MRI) approaches using nanoparticle contrast agents that can highlight beta cells without radiation. Early-stage work at institutions including the Icahn School of Medicine at Mount Sinai has shown feasibility in animal models, but human validation is still years away.
Current Status (2025)
GLP-1R-PET imaging with [68Ga]-exendin-4 is the most clinically advanced BCM imaging technique available. It is being used in research settings at select academic medical centers in Europe and the United States, but it is not yet available as a clinical diagnostic tool outside of trials. No BCM imaging technique has received FDA approval for routine clinical use. Standardization of imaging protocols, tracer production, and cost remain significant barriers to widespread adoption.
Patients interested in participating in BCM imaging studies can search ClinicalTrials.gov using the terms "beta cell mass imaging" or "GLP-1 receptor PET" to find enrolling studies.
Timeline: When Could This Reach Patients?
Optimistic projections from researchers suggest that a validated, standardized GLP-1R-PET protocol could be available at major academic diabetes centers within 5 to 8 years, assuming ongoing trials confirm reproducibility and clinical utility. Routine clinical availability β the kind that would appear alongside standard labs at endocrinology appointments β is realistically a 10 to 15 year horizon. MRI-based approaches, while radiation-free, lag further behind.
What This Means for Patients
For people living with diabetes today, BCM imaging is not yet part of your care. But its development matters enormously for the future. Better BCM measurement tools will help researchers design smarter clinical trials, identify which patients will respond to beta cell-preserving therapies like teplizumab, and eventually help doctors personalize treatment in ways that simply aren't possible today.
For people newly diagnosed with Type 1 diabetes β especially children β preserving whatever beta cell mass remains at diagnosis is a clinical priority right now. Treatments like teplizumab are available today. Staying informed through resources like mdsdiabetes.com can help you access current best-practice management while the next generation of tools is developed.
The ability to look inside a living pancreas and count its beta cells was science fiction a decade ago. It is now science in progress β and the progress is real.